The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...

Monoclonal antibodies (mAbs) are medications that target specific proteins to help reduce inflammation in people with severe asthma. The FDA has approved six mAbs for asthma treatment so far.

AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background ...

Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden (M. Laudette, M ...

Non-oncology expansion: ebronucimab (PCSK9) approved, NDAs for ebdarokimab (IL-12/IL-23) and gumokimab (IL-17) under review. 3 drugs approved, 5 new drugs with 5 indications under regulatory review.

Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization. In 2024, Akeso ...

durvalumab + chemotherapy as 1L treatment for biliary tract cancer Ivonescimab + AK117 (CD47 mAb) vs. pembrolizumab ... also advancing with the launch of PCSK9 inhibitor ebronucimab and the ...